Physician profile
Andrea T Murina
NPI 1295994218
$890,918.24
in general payments reported to CMS, 2019-2025
32 companies · $238K in 2025
The $238K reported for 2025 was more than what 96% of Clinical & Laboratory Dermatological Immunology providers received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $47K · 2021: $49K · 2022: $103K · 2023: $151K · 2024: $219K · 2025: $238K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $443K · Consulting Fee: $102K · Travel and Lodging: $47K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,400 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $443,264.82 |
| Consulting Fee | $102,335.75 |
| Travel and Lodging | $46,634.07 |
| Food and Beverage | $13,596.63 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,400.00 |
| Education | $193.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $153,517.14 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $144,813.35 | 2020-2025 | Bimzelx |
| Abbvie INC. | $112,882.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $108,356.14 | 2021-2025 | Sotyktu |
| Amgen INC. | $96,582.81 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $59,103.24 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $54,867.80 | 2019-2025 | Cosentyx |
| Janssen Scientific Affairs, LLC | $49,390.71 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $39,895.02 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Botanix Sb INC | $19,663.87 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16,873.17 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Takeda Pharmaceuticals U.S.A., INC. | $10,811.61 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,266.27 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $5,498.51 | 2019-2025 | Nemluvio |
| Celgene Corporation | $3,044.65 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,639.76 | 2020-2025 | |
| Mirum Pharmaceuticals, INC. | $1,625.00 | 2025 | Ctexli |
| Genzyme Corporation | $441.87 | 2019-2025 | |
| Leo Pharma INC. | $174.03 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $118.02 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $59.76 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $56.87 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $46.53 | 2019-2024 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $37.70 | 2023 | Valchlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.99 | 2024 | |
| Mallinckrodt Hospital Products INC. | $26.21 | 2025 | Acthar |
| Janssen Global Services, LLC | $25.12 | 2022 | |
| Kerecis Limited | $22.05 | 2022 | |
| Organon LLC | $17.01 | 2025 | |
| Mayne Pharma Commercial LLC | $14.76 | 2019 | |
| Genentech USA, INC. | $12.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Murina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.